Status:
COMPLETED
A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
Lead Sponsor:
Eli Lilly and Company
Conditions:
Mucinous Gastrointestinal Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.
Eligibility Criteria
Inclusion
- Able to take care of self. Out of bed less than 50% of the day
- Absolute neutrophil count \>=1,500
- Platelet count \>=100,000
- Total bilirubin count \<=1.5 times the upper limit of normal
Exclusion
- Prior epidermal growth factor receptor antibody
- Prior treatment with Erbitux
- Other cancers
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00162110
Start Date
November 1 2004
End Date
January 1 2007
Last Update
October 28 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
New York, New York, United States
2
Local Institution
Cincinnati, Ohio, United States